The DOI matches its Crossref record; 641 of the 641 references it cites were found in a registry or an index.
Hepatocellular carcinoma: signaling pathways and therapeutic advances
Open accessAbstract
Liver cancer represents a major global health concern, with projections indicating that the number of new cases could surpass 1 million annually by 2025. Hepatocellular carcinoma (HCC) constitutes around 90% of liver cancer cases and is primarily linked to factors incluidng aflatoxin, hepatitis B (HBV) and C (HCV), and metabolic disorders. There are no obvious symptoms in the early stage of HCC, which often leads to delays in diagnosis. Therefore, HCC patients usually present with tumors in advanced and incurable stages. Several signaling pathways are dis-regulated in HCC and cause uncontrolled cell propagation, metastasis, and recurrence of HCC. Beyond the frequently altered and therapeutically targeted receptor tyrosine kinase (RTK) pathways in HCC, pathways involved in cell differentiation, telomere regulation, epigenetic modification and stress response also provide therapeutic potential. Investigating the key signaling pathways and their inhibitors is pivotal for achieving therapeutic advancements in the management of HCC. At present, the primary therapeutic approaches for advanced HCC are tyrosine kinase inhibitors (TKI), immune checkpoint inhibitors (ICI), and combination regimens. New trials are investigating combination therapies involving ICIs and TKIs or anti-VEGF (endothelial growth factor) therapies, as well as combinations of two immunotherapy regimens. The outcomes of these trials are expected to revolutionize HCC management across all stages. Here, we provide here a comprehensive review of cellular signaling pathways, their therapeutic potential, evidence derived from late-stage clinical trials in HCC and discuss the concepts underlying earlier clinical trials, biomarker identification, and the development of more effective therapeutics for HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 601–641 of 641
Shekh, R., Tiwari, R. K., Ahmad, A., Ahmad, I., Alabdallah, N. M., Saeed, M., Ansari, I. A., Mishra, A., Ashfaque, M., & Bajpai, P. (2022) · Journal of Food Biochemistry · doi:10.1111/jfbc.14368 · Cited by 20
Xu, W., Shi, Z., Yu, X., Xu, Y., Chen, Y., He, Y., Gong, Y., Huang, C., Tan, C., & Yang, Y. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175423 · Cited by 20
Zhang, C., Zeng, Z., Zhuo, M., Luo, J., Zhuang, X.-H., Xu, J.-N., Zeng, J., Ma, J., & Lin, H. (2023) · The Oncologist · doi:10.1093/oncolo/oyad169 · Cited by 20
Alshammari, K. M., Alotaibi, F., Alsugheir, F., Aldawoud, M., Alolayan, A. A. M., Algarni, M., Sabatin, F., Mohammad, M. F., Alosaimi, A., Sanai, F. M., et al. (2023) · Cancers · doi:10.3390/cancers16010133 · Cited by 20
Reiss, K. A., Wattenberg, M. M., Damjanov, N., Dunphy, E. P., Jacobs-Small, M., Lubas, M. J., Robinson, J., Dicicco, L., Garcia-Marcano, L., Giannone, M. A., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0632 · Cited by 19
Xin, Z., Li, J., Zhang, H., Zhou, Y., Song, J., Chen, P., Bai, L., Chen, H., Zhou, J., Chen, J., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.783109 · Cited by 19
Self-citationXu, C., Gao, X., Ren, T., Geng, H., Yang, K., Huang, Y., Zhang, W., Hou, S., Song, A., Zhang, Y., et al. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107142 · Cited by 19
Wang, Q., Liu, F., Qi, S., Qi, Z., Yan, X.-E., Wang, B., Wang, A., Wang, W., Cheng, C., Liu, X., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.03.003 · Cited by 17
Missense Mutations in Exons 18–24 of EGFR in Hepatocellular Carcinoma Tissues
Panvichian, R., Tantiwetrueangdet, A., Sornmayura, P., & Leelaudomlipi, S. (2015) · BioMed Research International · doi:10.1155/2015/171845 · Cited by 16
Yin, L., He, J., Xue, J., Na, F., Tong, R., Wang, J., Gao, H., Tang, F., Mo, X., Deng, L., et al. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.01.095 · Cited by 16
Mechanism-guided fine-tuned microbiome potentiates anti-tumor immunity in HCC
Liu, T., Guo, Y., Liao, Y., & Liu, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1333864 · Cited by 16
The role of the microbiome in liver disease
Schöler, D., & Schnabl, B. (2024) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000001013 · Cited by 16
Shen, B., Shi, J.-P., Zhu, Z., He, Z., Liu, S., Shi, W., Zhang, Y., Ying, H., Wang, J., Xu, R.-F., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0096 · Cited by 15
Luo, H. L., Liu, W., Liang, H., Yan, H.-T., Lin, N., Li, D., Wang, T., & Tang, L. (2018) · Oncotarget · doi:10.18632/oncotarget.24421 · Cited by 14
Liu, J. L., Liu, Y., Zhang, J., Liu, D., Bao, Y., Chen, T., Tang, T., Lin, J., Luo, Y., Jin, Y., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03388-2 · Cited by 14
Zheng, Y., Tang, L., Chen, G., & Liu, Z. (2020) · Technology in Cancer Research & Treatment · doi:10.1177/1533033820983284 · Cited by 14
Chen, X., Zhao, Y.-X., Zhang, C., Wang, X., Zhang, X., Chen, X., Yuan, C.-W., Zhao, Q. C., & Chen, X. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s358092 · Cited by 14
Du, G., Yang, R., Qiu, J., & Xia, J. L. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00079 · Cited by 14
Peng, Y., Peng, Y., Xu, J., Xu, J., Xue-Mei, Y., Xue-Mei, Y., Huang, Y.-Y., Huang, Y.-Y., Li, L., Qi, L., et al. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2283160 · Cited by 14
Inhibition of the Ras oncoprotein reduces proliferation of hepatocytes in vitro and in vivo in rats
Morais, A. D. S., Saliez, A., Leclercq, I. A., Horsmans, Y., & Stärkel, P. (2007) · Clinical Science · doi:10.1042/cs20070152 · Cited by 13
Lu, Y., Liu, Y., Lan, J., Chan, Y.-T., Feng, Z., Huang, L., Wang, N., Pan, W., & Feng, Y. (2022) · Journal of Advanced Research · doi:10.1016/j.jare.2022.10.017 · Cited by 13
Okusaka, T., Morimoto, M., Eguchi, Y., Nakamura, S., Iino, S., & Kageyama, R. (2023) · Drugs in R&D · doi:10.1007/s40268-023-00416-8 · Cited by 13
Evaluation of NCAM and c-Kit as hepatic progenitor cell markers for intrahepatic cholangiocarcinomas
Xu, J., Tan, Y., Shao, X., Zhang, C., He, Y., Wang, J., & Xi, Y. (2018) · Pathology - Research and Practice · doi:10.1016/j.prp.2018.09.005 · Cited by 12
Emiloju, O. E., Yin, J., Koubek, E. J., Reid, J. M., Borad, M. J., Lou, Y., Seetharam, M., Edelman, M. J., Sausville, E. A., Jiang, Y., et al. (2024) · Investigational New Drugs · doi:10.1007/s10637-024-01420-8 · Cited by 12
Wu, Y., Xu, X., Liu, M., Qin, X., Wu, Q., Ding, H., & Zhao, Q. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115093 · Cited by 11
Epigenetic mechanisms of liver tumor resistance to immunotherapy
Sanceau, J., & Gougèlet, A. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i9.979 · Cited by 10
Golonka, R. M., Yeoh, B. S., Saha, P., Gohara, A. F., Tummala, R., Stepkowski, S. M., Tiwari, A. K., Joe, B., Gonzalez, F. J., Gewirtz, A. T., et al. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000166 · Cited by 10
Jung, Y. Y., Kim, C., Shanmugam, M. K., Deivasigamani, A., Chinnathambi, A., Alharbi, S. A., Rangappa, K. S., Hui, K. M., Sethi, G., Mohan, C. D., et al. (2023) · Cellular Signalling · doi:10.1016/j.cellsig.2023.111003 · Cited by 10
Telomerase: a good target in hepatocellular carcinoma? An overview of relevant preclinical data
Tornesello, M. L., Tornesello, A. L., Starita, N., Cerasuolo, A., Izzo, F., Buonaguro, L., & Buonaguro, F. M. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2147062 · Cited by 9
Mohammed, O. A., Doghish, A. S., Saleh, L. A., Alghamdi, M. A. A., Alamri, M. M. S., Alfaifi, J. A., Adam, M. I. E., Alharthi, M. H., Alshahrani, A. M., Alhalafi, A. H., et al. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.155086 · Cited by 9
Li, C.-L., Wang, C.-C., Pai, H.-T., Tu, S.-L., Hou, P.-Y., Huang, C., Huang, M., & Chang, Y. (2022) · Disease Markers · doi:10.1155/2022/8316335 · Cited by 8
Chien, S.-C., Lin, Y., Lee, C., Chiu, Y., Chou, T.-C., Chiu, H., Tsai, H., Su, C.-M., Yang, T.-H., Chiang, H., et al. (2022) · Viruses · doi:10.3390/v14112427 · Cited by 8
Chen, W., Chen, F., Gong, M., Ye, L., Weng, D., Jin, Z., & Wang, J. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02604-4 · Cited by 8
Xiong, Y., Zhang, Y., & Hu, C. (2024) · Translational Cancer Research · doi:10.21037/tcr-23-1939 · Cited by 8
Anti-hepatoma effect of taccalonolide A through suppression of sonic hedgehog pathway
Tian, H., & He, Z. (2020) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2020.1773484 · Cited by 7
Fu, L. L., Guo, L., Zheng, Y., et al. (2018) · Oncology Letters · doi:10.3892/ol.2018.7933 · Cited by 6
Tomimaru, Y., Aihara, A., Wands, J. R., Aloman, C., & Kim, M. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.07.002 · Cited by 6
Prognostic analysis of RAS-related lncRNAs in liver hepatocellular carcinoma
Ding, L., Fan, X., Zuo, L., Wu, X., Wu, Y., Zhang, Y., Zou, F., Sun, Z., & Zhang, W. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-5827 · Cited by 6
Self-citationDesign, synthesis, and biological evaluation of selective covalent inhibitors of FGFR4
Chen, X., Chen, X., Li, H., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116281 · Cited by 5
ETS-1/c-Met drives resistance to sorafenib in hepatocellular carcinoma.
Ma, Y., Liu, X., & Tang, X. (2023) · PubMed Central · Cited by 4
Maia, M. L. P., Albuquerque, R. M., Silva, S. D. D. C., Lima, C. X., Diniz, P. H. C., & Vidigal, P. V. T. (2023) · Oncology · doi:10.1159/000535332 · Cited by 3
Metadata
- Authors
- Zheng, J., Wang, S., Xia, L., Sun, Z., Chan, K. M., Bernards, R., Qin, W., Chen, J., Xia, Q., & Jin, H.
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2025-02-07
- Volume
- 10
- Issue
- 1
- Pages
- 35-35
- ISSN
- 2059-3635 (ISSN-L)
- OpenAlex
- W4407203105
- Cited by
- 341
- References
- 641
- FWCI
- 165.95
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.